Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Granulomatosis with Polyangiitis Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Granulomatosis with Polyangiitis Drugmarket, defines the market attractiveness level of Granulomatosis with Polyangiitis Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Granulomatosis with Polyangiitis Drug industry, describes the types of Granulomatosis with Polyangiitis Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Granulomatosis with Polyangiitis Drug market and the development prospects and opportunities of Granulomatosis with Polyangiitis Drug industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Granulomatosis with Polyangiitis Drug market in Chapter 13.
By Player:
Coherus BioSciences Inc
ChemoCentryx Inc
Bionovis SA
The International Biotechnology Center (IBC) Generium
Sandoz International GmbH
Genor BioPharma Co Ltd
Bristol-Myers Squibb Company
Panacea Biotec Ltd
Iltoo Pharma
GlaxoSmithKline Plc
By Type:
Benralizumab
Avacopan
Rituximab Biosimilar
Others
By End-User:
Hospital
Clinic
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Granulomatosis with Polyangiitis Drug Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Granulomatosis with Polyangiitis Drug Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Granulomatosis with Polyangiitis Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Granulomatosis with Polyangiitis Drug Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Granulomatosis with Polyangiitis Drug Market Analysis and Outlook to 2022
-
7.1 Global Granulomatosis with Polyangiitis Drug Consumption (2017-2022)
-
7.2 United States Granulomatosis with Polyangiitis Drug Consumption (2017-2022)
-
7.3 Europe Granulomatosis with Polyangiitis Drug Consumption (2017-2022)
-
7.4 China Granulomatosis with Polyangiitis Drug Consumption (2017-2022)
-
7.5 Japan Granulomatosis with Polyangiitis Drug Consumption (2017-2022)
-
7.6 India Granulomatosis with Polyangiitis Drug Consumption (2017-2022)
-
7.7 South Korea Granulomatosis with Polyangiitis Drug Consumption (2017-2022)
8 Region and Country-wise Granulomatosis with Polyangiitis Drug Market Analysis and Outlook to 2028
-
8.1 Global Granulomatosis with Polyangiitis Drug Consumption Forecast (2022-2028)
-
8.2 United States Granulomatosis with Polyangiitis Drug Consumption Forecast (2022-2028)
-
8.3 Europe Granulomatosis with Polyangiitis Drug Consumption Forecast (2022-2028)
-
8.4 China Granulomatosis with Polyangiitis Drug Consumption Forecast (2022-2028)
-
8.5 Japan Granulomatosis with Polyangiitis Drug Consumption Forecast (2022-2028)
-
8.6 India Granulomatosis with Polyangiitis Drug Consumption Forecast (2022-2028)
-
8.7 South Korea Granulomatosis with Polyangiitis Drug Consumption Forecast (2022-2028)
9 Global Granulomatosis with Polyangiitis Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Granulomatosis with Polyangiitis Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Benralizumab Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Avacopan Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Rituximab Biosimilar Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Granulomatosis with Polyangiitis Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Granulomatosis with Polyangiitis Drug Market Outlook by Types and Applications to 2028
-
10.1 Global Granulomatosis with Polyangiitis Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Benralizumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Avacopan Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Rituximab Biosimilar Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Granulomatosis with Polyangiitis Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Granulomatosis with Polyangiitis Drug Import and Export Analysis (Top 5 Countries)
-
11.1 Global Granulomatosis with Polyangiitis Drug Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Granulomatosis with Polyangiitis Drug Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Granulomatosis with Polyangiitis Drug Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Granulomatosis with Polyangiitis Drug Market Competitive Analysis
-
14.1 Coherus BioSciences Inc
-
14.1.1 Coherus BioSciences Inc Company Details
-
14.1.2 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Service
-
14.2 ChemoCentryx Inc
-
14.2.1 ChemoCentryx Inc Company Details
-
14.2.2 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Service
-
14.3 Bionovis SA
-
14.3.1 Bionovis SA Company Details
-
14.3.2 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Bionovis SA Granulomatosis with Polyangiitis Drug Product and Service
-
14.4 The International Biotechnology Center (IBC) Generium
-
14.4.1 The International Biotechnology Center (IBC) Generium Company Details
-
14.4.2 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Service
-
14.5 Sandoz International GmbH
-
14.5.1 Sandoz International GmbH Company Details
-
14.5.2 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Service
-
14.6 Genor BioPharma Co Ltd
-
14.6.1 Genor BioPharma Co Ltd Company Details
-
14.6.2 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Service
-
14.7 Bristol-Myers Squibb Company
-
14.7.1 Bristol-Myers Squibb Company Company Details
-
14.7.2 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Service
-
14.8 Panacea Biotec Ltd
-
14.8.1 Panacea Biotec Ltd Company Details
-
14.8.2 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Service
-
14.9 Iltoo Pharma
-
14.9.1 Iltoo Pharma Company Details
-
14.9.2 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Service
-
14.10 GlaxoSmithKline Plc
-
14.10.1 GlaxoSmithKline Plc Company Details
-
14.10.2 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Granulomatosis with Polyangiitis Drug
-
Figure Granulomatosis with Polyangiitis Drug Picture
-
Table Global Granulomatosis with Polyangiitis Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Granulomatosis with Polyangiitis Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Granulomatosis with Polyangiitis Drug Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Granulomatosis with Polyangiitis Drug Consumption by Country (2017-2022)
-
Figure United States Granulomatosis with Polyangiitis Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Granulomatosis with Polyangiitis Drug Consumption and Growth Rate (2017-2022)
-
Figure China Granulomatosis with Polyangiitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Granulomatosis with Polyangiitis Drug Consumption and Growth Rate (2017-2022)
-
Figure India Granulomatosis with Polyangiitis Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Granulomatosis with Polyangiitis Drug Consumption and Growth Rate (2017-2022)
-
Figure Global Granulomatosis with Polyangiitis Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Granulomatosis with Polyangiitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Granulomatosis with Polyangiitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Granulomatosis with Polyangiitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Granulomatosis with Polyangiitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Granulomatosis with Polyangiitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Granulomatosis with Polyangiitis Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Benralizumab Consumption and Growth Rate (2017-2022)
-
Figure Global Avacopan Consumption and Growth Rate (2017-2022)
-
Figure Global Rituximab Biosimilar Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Benralizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Avacopan Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Rituximab Biosimilar Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Granulomatosis with Polyangiitis Drug Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Granulomatosis with Polyangiitis Drug Export by Region (Top 5 Countries) (2017-2028)
-
Table Coherus BioSciences Inc (Foundation Year, Company Profile and etc.)
-
Table Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product and Service
-
Table ChemoCentryx Inc (Foundation Year, Company Profile and etc.)
-
Table ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product and Service
-
Table Bionovis SA (Foundation Year, Company Profile and etc.)
-
Table Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bionovis SA Granulomatosis with Polyangiitis Drug Product and Service
-
Table The International Biotechnology Center (IBC) Generium (Foundation Year, Company Profile and etc.)
-
Table The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product and Service
-
Table Sandoz International GmbH (Foundation Year, Company Profile and etc.)
-
Table Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product and Service
-
Table Genor BioPharma Co Ltd (Foundation Year, Company Profile and etc.)
-
Table Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product and Service
-
Table Bristol-Myers Squibb Company (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product and Service
-
Table Panacea Biotec Ltd (Foundation Year, Company Profile and etc.)
-
Table Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product and Service
-
Table Iltoo Pharma (Foundation Year, Company Profile and etc.)
-
Table Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Iltoo Pharma Granulomatosis with Polyangiitis Drug Product and Service
-
Table GlaxoSmithKline Plc (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product and Service
-
